Clinical trials: Mental Disorder
Alzheimer's Disease
QTc Study of Rosi XR in Healthy Volunteers
This study is a randomised double blind, parallel group, and will evaluate the effects of repeat oral doses of RSG- XR for 21 days on the QTc interval compared to placebo in a population of healthy adult males and females.
- Trial name
- Rosi XR (NCT00884533)
- Testing
- Rosi XR, Moxifloxacin
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer Disease, Cognitive Impairment
The REMIND Study- SPARK Neuro Software Study
The study utilizes investigational software, the SPARK Test, with an FDA-cleared electroencephalography (EEG) amplifier and EEG cap to collect and patient EEG data.
- Trial name
- NCT05406778
- Testing
- SPARK Test
- Where
- 7 sites in United States
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Spark Neuro Inc.
Alcohol Abuse
Adaptive Goal-Directed Adherence Tracking and Enhancement
Talaria, Inc., has designed an adherence tracking and enhancement system, called AGATE, which uses the text messaging and internet capabilities of modern cellular phones to address the problem of medication adherence in clinical…
- Trial name
- AGATE (NCT01349985)
- Testing
- AGATE, SASED
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Talaria, Inc
Attention-Deficit/Hyperactivity Disorder
Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
Open label, flexible dose, long-term multicenter study of safety and efficacy of SPN-812 in adult ADHD patients
- Trial name
- NCT04143217
- Testing
- SPN-812
- Where
- 38 sites in United States
- Volunteers
- 159 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Major Depressive Disorder
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
This is a Phase 2 clinical study evaluating the safety and effectiveness of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
- Trial name
- NCT04479852
- Testing
- SP-624
- Where
- 39 sites in United States
- Volunteers
- 319 people
- Sponsor
- Sirtsei Pharmaceuticals, Inc.
Schizophrenia
Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
The purpose of the protocol is to evaluate the efficacy of olanzapine compared with Aripiprazole in patients with schizophrenia.
- Trial name
- NCT00088049
- Testing
- Olanzapine, Aripiprazole
- Where
- 24 sites in United States
- Volunteers
- 560 people
- Sponsor
- Eli Lilly and Company
Memory Impairment, Dementia, Vascular
CognivAiD Real-World Evidence Clinical Registry (CONNECT Registry)
This is an observational, prospective cohort of patients who were prescribed or have taken CognivAiD as prescribed by the attending physician. The safety and efficacy of CognivAiD have been established in clinical studies.
- Trial name
- CONNECT (NCT06228638)
- Testing
- CognivAID (Sailuotong)
- Where
- Singapore
- Volunteers
- 100 people
- Sponsor
- Moleac Pte Ltd.
Alzheimer's Disease
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug lanabecestat in participants with early Alzheimer's disease dementia…
- Trial name
- NCT02972658
- Testing
- Lanabecestat
- Where
- 133 sites in United States, Australia and 12 more
- Volunteers
- 421 people
- Sponsor
- AstraZeneca
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure
The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor [SSRI] or serotonin-norepinephrine reuptake inhibitor…
- Trial name
- VENTURA-5 (NCT06635135)
- Testing
- Aticaprant
- Where
- 95 sites in United States, Argentina and 11 more
- Volunteers
- 47 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
Safety and Tolerability of Risperidone Implants
A one year, open-label, study to evaluate the safety and tolerability of risperidone implants as a maintenance treatment in patients with schizophrenia
- Trial name
- NCT02773576
- Testing
- Risperidone implant
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Braeburn Pharmaceuticals
Mild Cognitive Impairment, Alzheimer's Disease
A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers
Xanamem® is being developed as a potential drug for Mild Cognitive Impairment in Alzheimer's disease. This study drug has been designed to change the cortisol levels in the brain.
- Trial name
- XanaMIA-DR (NCT04983368)
- Testing
- Xanamem® 5 mg, Xanamem® 10 mg
- Where
- 5 sites in Australia
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Actinogen Medical
Healthy, Epilepsy
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
The human brain presents outstanding challenges to science and medicine. Brain function and structure span broad spatial scales (from single neurons to brain-wide networks) as well as temporal scales (from milliseconds to years).
- Conditions
- Healthy, Epilepsy, Psychosis, Essential Tremor
- Trial name
- NCT05769933
- Testing
- Simultaneous EEG-fMRI at 7 Tesla, Structural MRI at 7 Tesla
- Where
- Switzerland
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Developpement
Lewy Body Disease
A Phase I Study of GT300 in Healthy Subjects
Descriptive safety and pharmacokinetics of GT300, exploratory biomarker effects for the evaluation of the effect of GT300 on the autophagy-lysosomal pathway (ALP), food effect on PK and fasting effect on biomarkers.
- Trial name
- NCT04963855
- Testing
- GT300, Microcrystalline cellulose
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Generian Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of Impulsive Aggression (IA) in subjects with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with…
- Trial name
- NCT02618408
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 28 sites in United States
- Volunteers
- 333 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Schizophrenia
Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia
A study to investigate the process by which ABT-126 is absorbed, distributed, metabolized and eliminated by the body of stable schizophrenic volunteers receiving treatment with an atypical antipsychotic.
- Trial name
- NCT01043458
- Testing
- ABT-126
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Abbott
Major Depressive Disorder
Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)
The primary objective of this study is to evaluate the long-term safety of desvenlafaxine succinate sustained release tablets during 10-month open-label treatment of Japanese subjects with major depressive disorder (MDD).
- Trial name
- NCT00831415
- Testing
- desvenlafaxine succinate sustained release tablets
- Where
- 17 sites in Japan
- Volunteers
- 304 people
- Sponsor
- Pfizer
Narcolepsy
Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients
This Phase 2 study is a 8-site, double-blind, randomised, placebo-controlled, 3-way cross-over trial, involving 3 treatments with Modafinil 300 mg or the combination drug THN102 (Modafinil/Flecainide 300 /3 mg…
- Trial name
- NCT02821715
- Testing
- THN102 300/3, THN102 300/27
- Where
- 8 sites in Belgium, France
- Volunteers
- 51 people
- Sponsor
- Theranexus
Treatment Resistant Depression
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
The purpose of this study is to determine if CX157 is effective and safe in patients with treatment of treatment resistant depression over six weeks of treatment.
- Trial name
- CX157-201 (NCT01246908)
- Testing
- CX157 (TriRima)
- Where
- 30 sites in United States
- Volunteers
- 360 people
- Sponsor
- CeNeRx BioPharma Inc.
Stress Urinary Incontinence
Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence
This study evaluates the efficacy and safety of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR; generic name: iltamiocel) compared to a placebo in the reduction of stress incontinence episode frequency in…
- Trial name
- CELLEBRATE (NCT03104517)
- Testing
- AMDC-USR (iltamiocel)
- Where
- 21 sites in United States, United Kingdom
- Volunteers
- 96 people
- Sponsor
- Cook MyoSite
Narcolepsy, Excessive Sleepiness
Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy
This trial is a randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of JZP-110 on driving performance in subjects with excessive sleepiness due to narcolepsy.
- Trial name
- NCT02806908
- Testing
- JZP-110
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Jazz Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.